Showing 1 - 7 of 7
We empirically analyze the welfare effects of cross-firm bundling in the pharmaceutical industry. Physicians often treat patients with "cocktail" regimens that combine two or more drugs. Firms cannot price discriminate because each drug is produced by a different firm and a physician creates the...
Persistent link: https://www.econbiz.de/10008533391
Persistent link: https://www.econbiz.de/10011946947
"The NBER Bulletin on Aging and Health provides summaries of publications like this. You can sign up to receive the NBER Bulletin on Aging and Health by email. We empirically analyze the welfare effects of cross-firm bundling in the pharmaceutical industry. Physicians often treat patients with...
Persistent link: https://www.econbiz.de/10008695771
Persistent link: https://www.econbiz.de/10008660606
We empirically analyze the welfare effects of cross-firm bundling in the pharmaceutical industry. Physicians often treat patients with "cocktail" regimens that combine two or more drugs. Firms cannot price discriminate because each drug is produced by a different firm and a physician creates the...
Persistent link: https://www.econbiz.de/10012462336
Persistent link: https://www.econbiz.de/10008639235
We empirically analyze the welfare effects of cross-firm bundling in the pharmaceutical industry. Physicians often treat patients with "cocktail" regimens that combine two or more drugs. Firms cannot price discriminate because each drug is produced by a different firm and a physician creates the...
Persistent link: https://www.econbiz.de/10013138761